FDA Import Refusal 799-1912846-3/21/1 — AstraZeneca Pharmaceuticals LP
The FDA refused shipment 799-1912846-3/21/1 from AstraZeneca Pharmaceuticals LP (United States) on Jul 17, 2024. The refused product falls under Drugs and Biologics — DAPAGLIFLOZIN (ANTI-DIABETIC). Cited charge: 75 This firm has 5 or more other import refusals on record.
Refusal Details
- Date
- Jul 17, 2024
- Country
- United States
- Product Category
- Drugs and Biologics
- Product Code
- 61PDA70 DAPAGLIFLOZIN (ANTI-DIABETIC)
- Charges
- 75